Compare Stocks

→ $25,000 into $109,616 in two months? (From WealthPress) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$13.60 +6.8%	$10.49	$5.42 ▼ $22.49	$149.74M	1.59	268,984 shs	329,659 shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	+7.18%	+40.68%	+7.23%	+40.07%	-13.61%

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	2.0646 of 5 stars	3.4	2.0	0.0	0.0	2.8	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.75	Moderate Buy	$27.75	104.04% Upside

Current Analyst Ratings

Latest ANVS, REDX, SCLP, TILS, and FARN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2024	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
3/21/2024	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
2/28/2024	ANVS Annovis Bio	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$9.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	($0.73) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$56.20M	-$6.22	N/A	N/A	N/A	N/A	-446.06%	-257.97%	5/9/2024 (Estimated)

Latest ANVS, REDX, SCLP, TILS, and FARN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/29/2024	Q4 2023	ANVS Annovis Bio	N/A	-$1.09	-$1.09	$0.15	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	2.39	2.39

Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	38.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	6	11.01 million	6.79 million	Optionable

ANVS, REDX, SCLP, TILS, and FARN Headlines

Source	Headline
	Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade zacks.com - April 24 at 10:56 AM
	Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals finance.yahoo.com - April 17 at 1:33 PM
	Annovis Bio Sees Unusually High Options Volume (NYSE:ANVS) americanbankingnews.com - April 17 at 2:38 AM
	Traders Buy High Volume of Call Options on Annovis Bio (NYSE:ANVS) marketbeat.com - April 16 at 10:35 AM
	Annovis Bio, Inc. (NYSE:ANVS) Sees Significant Growth in Short Interest americanbankingnews.com - April 15 at 4:14 AM
	Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High? zacks.com - April 8 at 10:56 AM
	Annovis Bio Makes Strides in Neurodegenerative Disease Treatment: 2023 Q4 Results Below Projections, Progress Seen in Clinical Trials msn.com - April 4 at 10:32 AM
	Q1 2024 Earnings Estimate for Annovis Bio, Inc. Issued By Brookline Capital Management (NYSE:ANVS) marketbeat.com - April 4 at 8:48 AM
	Annovis Bio's Buntanetap Shows Promise in Early Alzheimer’s Disease Study msn.com - April 3 at 8:18 AM
	Equities Analysts Issue Forecasts for Annovis Bio, Inc.'s Q1 2025 Earnings (NYSE:ANVS) marketbeat.com - April 3 at 6:30 AM
	Annovis Bio, Inc. (NYSE:ANVS) Short Interest Down 8.2% in March marketbeat.com - April 2 at 10:12 PM
	Buy Rating Reiterated for Annovis Bio Amid Anticipated Positive Trial Results for Alzheimer’s and Parkinson’s Treatments markets.businessinsider.com - April 2 at 4:21 PM
	ANVS Stock Earnings: Annovis Bio Misses EPS for Q4 2023 investorplace.com - April 2 at 2:13 PM
	Annovis Bio (NYSE:ANVS) Rating Reiterated by HC Wainwright marketbeat.com - April 2 at 9:12 AM
	Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results globenewswire.com - April 2 at 7:30 AM
	Annovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in Humans globenewswire.com - April 1 at 8:00 AM
	Annovis Bio Inc Aktie: Unfassbarer Gewinn! aktiencheck.de - March 30 at 12:00 PM
	Annovis Bio Nears Milestone in Alzheimer’s Treatment Study with Completion of Data Cleaning msn.com - March 24 at 7:05 PM
	Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a Bet zacks.com - March 21 at 10:56 AM
	Annovis Bio Shares Up 31% on Progress Toward Reporting Data From Alzheimer's Study marketwatch.com - March 21 at 7:57 AM
	Annovis Bio Completes Data Cleaning for Buntanetap Study marketwatch.com - March 20 at 9:49 PM
	ANVS Jul 2024 30.000 call finance.yahoo.com - March 20 at 4:49 PM
	Annovis to release efficacy data on Alzheimer's drug in April msn.com - March 20 at 4:49 PM
	Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease globenewswire.com - March 20 at 7:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Annovis Bio

NYSE:ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial